Journal: Molecular Biology of the Cell

Article Title: Image-based drug screen identifies HDAC inhibitors as novel Golgi disruptors synergizing with JQ1

doi: 10.1091/mbc.E17-03-0176

Figure Lengend Snippet: Image-based chemical compound screen identifies HDAC inhibitors and DNA-damaging agents as novel Golgi-dispersing compounds. To identify novel compounds that modulate Golgi morphology, a screening platform was established. (A) Screening pipeline including cell seeding (A549 cells), treatment with compound library, staining for the cis -Golgi (GM130), the nucleus (Hoechst), the ER stress marker (GRP78), cytoplasm (Phalloidin), and image acquisition and processing. (B) Representative images of the negative control (vehicle-treated cells) as well as positive controls (BFA, doxorubicin, and nocodazole) and newly discovered Golgi-fragmenting drugs (Bleomycin, Vorinostat, 4-iodo-SAHA, Trichostatin A, Givinostat, and Pracinostat) are displayed. (C) Following image analysis, to exclude potential plate effects, the Golgi area of cells treated with the chemical library was normalized to the vehicle-treated sample present within the same plate. The corresponding survival ratios of treated cells are also shown. (D) Detailed view of compounds are shown, of which at least two of three replicates caused a ≥1.5-fold increase in Golgi area. The compound panel includes positive controls and novel Golgi-fragmenting compounds, which were selected for further investigation. *** p < 0.001 vs. #; see Materials and Methods .

Article Snippet: Compounds were obtained from the following companies: brefeldin A (Sigma-Aldrich), golgicide A (Santa Cruz Biotechnology), monensin (Enzo Life Sciences), AG-1478 (Sigma), tunicamycin (Santa Cruz Biotechnology), thapsigargin (Santa Cruz Biotechnology), nocodazole (Santa Cruz Biotechnology), (+)-JQ1 (Cayman Chemical), CBP30 (TargetMol), doxorubicin (Sigma), etoposide (Sigma), teniposide (Santa Cruz Biotechnology), mitomycin-C (Santa Cruz Biotechnology), cisplatin (Santa Cruz Biotechnology), hydroxyurea (Sigma), 5-fluorouracil (Sigma), gemcitabine (Santa Cruz Biotechnology), irinotecan (Santa Cruz Biotechnology), bleomycin (Santa Cruz Biotechnology), NU7441 (Selleckchem), KU55933 (Sigma), Flavopiridol (Santa Cruz Biotechnology), phorbol 12-myristate 13-acetate (PMA; Santa Cruz Biotechnology), Panobinostat (Selleckchem), Tubastatin (Selleckchem), Entinostat (Santa Cruz Biotechnology), Pracinostat (Selleckchem), Givinostat (Selleckchem), Triptolide (Santa Cruz Biotechnology), α-Amanitin (Santa Cruz Biotechnology), and Z-VAD-FMK (Santa Cruz Biotechnology).

Techniques: Drug discovery, Staining, Marker, Negative Control

Journal: Biomaterials

Article Title: HYDROGEL-BASED DELIVERY OF IL-10 IMPROVES TREATMENT OF BLEOMYCIN-INDUCED LUNG FIBROSIS IN MICE

doi: 10.1016/j.biomaterials.2019.02.017

Figure Lengend Snippet: A) ELISA quantification of IL-10 released from HH-10 formulation over 6 days (n=13). B)-C) Fluorescent microscopy images of lung tissue with fluorescently labeled HH reagent in both healthy (B) and bleomycin-challenged (C) lung tissue, displaying deposition locations of HH reagent via intranasal treatment. Images on right are high magnification of the squared regions.

Article Snippet: Two to four-month old wildtype C57Bl6J mice were treated with PBS control or bleomycin (MPBio, 0219030610) at a concentration of 1500–2000 international units/kg weight intratracheally; mice were anesthetized via ketamine/xylazine cocktail (K113–10ML, Sigma).

Techniques: Enzyme-linked Immunosorbent Assay, Microscopy, Labeling

Journal: Biomaterials

Article Title: HYDROGEL-BASED DELIVERY OF IL-10 IMPROVES TREATMENT OF BLEOMYCIN-INDUCED LUNG FIBROSIS IN MICE

doi: 10.1016/j.biomaterials.2019.02.017

Figure Lengend Snippet: A) Experimental design timeline of prevention cohort and analysis. B) Trichrome and α-SMA IHC stain of lung tissue sections by group of prevention cohorts, all parameters include bleomycin challenge. C) Sircol- assay quantifying collagen content of lung samples from healthy control and bleomycin challenged mice with preventative PBS, IL-10, HH, or HH-10. D) Ashcroft Score quantifying fibrosis of lung sections from healthy control and bleomycin challenged mice with preventative PBS, IL-10, HH, or HH-10. E) BAL cell counts from healthy control and bleomycin challenged mice with preventative PBS, IL-10, HH, or HH-10. For all graphs- ***p< .001 vs. PBS + BLM, **p< .01 vs. PBS + BLM, *p< .05 vs. PBS + BLM.

Article Snippet: Two to four-month old wildtype C57Bl6J mice were treated with PBS control or bleomycin (MPBio, 0219030610) at a concentration of 1500–2000 international units/kg weight intratracheally; mice were anesthetized via ketamine/xylazine cocktail (K113–10ML, Sigma).

Techniques: Staining

Journal: Biomaterials

Article Title: HYDROGEL-BASED DELIVERY OF IL-10 IMPROVES TREATMENT OF BLEOMYCIN-INDUCED LUNG FIBROSIS IN MICE

doi: 10.1016/j.biomaterials.2019.02.017

Figure Lengend Snippet: A) Experimental design timeline of treatment cohort and analysis. B) Trichrome IHC and α-SMA IHC stain of lung tissue sections of bleomycin-challenged treatment cohorts. C) Sircol- assay of lung samples from healthy control and bleomycin challenged mice with PBS, IL-10, HH, or HH-10 treatment. D) Ashcroft Score of lung sections from healthy control and bleomycin challenged mice with PBS, IL-10, HH, or HH-10 treatment. E) BAL cell counts from healthy control and bleomycin challenged mice with PBS, IL-10, HH, or HH-10 treatment. For all graphs- ***p< .001 vs. PBS + BLM, **p< .01 vs. PBS + BLM, *p< .05 vs. PBS + BLM.

Article Snippet: Two to four-month old wildtype C57Bl6J mice were treated with PBS control or bleomycin (MPBio, 0219030610) at a concentration of 1500–2000 international units/kg weight intratracheally; mice were anesthetized via ketamine/xylazine cocktail (K113–10ML, Sigma).

Techniques: Staining

Journal: Biomaterials

Article Title: HYDROGEL-BASED DELIVERY OF IL-10 IMPROVES TREATMENT OF BLEOMYCIN-INDUCED LUNG FIBROSIS IN MICE

doi: 10.1016/j.biomaterials.2019.02.017

Figure Lengend Snippet: A) IHC staining for phospho-Smad3 in bleomycin challenged mice treated in prevention or treatment regiments with PBS, IL-10, HH, or HH-10. B)-C) Quantification of pSmad3 positive cells from IHC images in bleomycin challenged mice treated in prevention or treatment regiments with PBS, IL-10, HH, or HH-10. For all graphs- ***p< .001 vs. PBS + BLM and **p< .01 vs. PBS + BLM.

Article Snippet: Two to four-month old wildtype C57Bl6J mice were treated with PBS control or bleomycin (MPBio, 0219030610) at a concentration of 1500–2000 international units/kg weight intratracheally; mice were anesthetized via ketamine/xylazine cocktail (K113–10ML, Sigma).

Techniques: Immunohistochemistry

Journal: Data in Brief

Article Title: Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension

doi: 10.1016/j.dib.2021.107747

Figure Lengend Snippet: Plasma levels of metabolism and tumour related proteins in controls and patients.

Article Snippet: NT-proBNP and 69 tumour and metabolism related proteins were analysed: 5′-nucleotidase (5′-NT), protein AMBP or alpha-1-microglobulin/bikunin precursor (AMBP), aminopeptidase N (AP-N), bleomycin hydrolase (BLM-H), brother of cell adhesion molecule-related/down-regulated by oncogenes (CDO) or (BOC), carbonic anhydrase 9 (CA9), cathepsin Z, cyclin-dependant kinase inhibitor 1A (CDKN1A) or p21, carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 1 and 5, contactin-1, cornulin, carboxypeptidase (CP) A1, B1 and E, cystatin B, decorin, endothelial cell-specific molecule 1 or endocan, epithelial cell adhesion molecule (EpCAM), fatty acid-binding protein 4 (FABP4), fibroblast growth factor (FGF-) 21 and 23, folate receptor gamma (FR-gamma), furin, gastrotropin, glyoxalase I or lactoylglutathione lyase, insulin-like growth factor 1 receptor (IGF1R), insulin-like growth factor-binding protein (IGFBP) 2, 3 and 7, kallikrein 6, 8, 11, 13 and 14, low-density lipoprotein receptor (LDL-R), leptin, lectin-like oxidized LDL receptor 1 (LOX-1), lipoprotein lipase (LPL), Ly6/PLAUR domain-containing protein 3 (LYPD3) or C4.4A, mesothelin, methionine aminopeptidase 2 (MetAP2), melanoma-derived growth regulatory protein (MIA), midkine, mucin-16 or CA125, nectin-4 or PVRL4, pappalysin-1, proprotein convertase subtilisin/kexin type 9 (PCSK9), podocalyxin, paraoxonase-3 (PON-3), prostasin, protein S100A4 (S100A4), protein S100A11 (S100A11), retinoic acid receptor responder protein 2 (RARRES2), resistin, secretory carrier-associated membrane protein 3 (SCAMP3), secretoglobin family 3A member 2 (SCGB3A2), serpin A12, tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS-1), sortillin, soluble receptor for advanced glycation end products (sRAGE; all soluble forms of RAGE), T-cell leukaemia/lymphoma protein 1A (TCL1A), trefoil factor 3 (TFF3), protein-glutamine gamma-glutamyltransferase 2 (TGM2), transferrin receptor protein 1 (TR), WAP four-disulfide core domain protein 2 (WFDC2), vimentin, V-set and immunoglobulin domain-containing protein 2 (VSIG2) and Xaa-Pro aminopeptidase 2 (XPNPEP2).

Techniques:

Journal: Data in Brief

Article Title: Data on plasma tumour and metabolism related proteins’ potential in differentiation of HFpEF-PH from PAH and in prognosis of left heart failure patients with pulmonary hypertension

doi: 10.1016/j.dib.2021.107747

Figure Lengend Snippet: Proteins’ classification and p-values of Kruskal Wallis and Mann Whitney's tests in comparing metabolism and tumour related proteins in controls and disease groups.

Article Snippet: NT-proBNP and 69 tumour and metabolism related proteins were analysed: 5′-nucleotidase (5′-NT), protein AMBP or alpha-1-microglobulin/bikunin precursor (AMBP), aminopeptidase N (AP-N), bleomycin hydrolase (BLM-H), brother of cell adhesion molecule-related/down-regulated by oncogenes (CDO) or (BOC), carbonic anhydrase 9 (CA9), cathepsin Z, cyclin-dependant kinase inhibitor 1A (CDKN1A) or p21, carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 1 and 5, contactin-1, cornulin, carboxypeptidase (CP) A1, B1 and E, cystatin B, decorin, endothelial cell-specific molecule 1 or endocan, epithelial cell adhesion molecule (EpCAM), fatty acid-binding protein 4 (FABP4), fibroblast growth factor (FGF-) 21 and 23, folate receptor gamma (FR-gamma), furin, gastrotropin, glyoxalase I or lactoylglutathione lyase, insulin-like growth factor 1 receptor (IGF1R), insulin-like growth factor-binding protein (IGFBP) 2, 3 and 7, kallikrein 6, 8, 11, 13 and 14, low-density lipoprotein receptor (LDL-R), leptin, lectin-like oxidized LDL receptor 1 (LOX-1), lipoprotein lipase (LPL), Ly6/PLAUR domain-containing protein 3 (LYPD3) or C4.4A, mesothelin, methionine aminopeptidase 2 (MetAP2), melanoma-derived growth regulatory protein (MIA), midkine, mucin-16 or CA125, nectin-4 or PVRL4, pappalysin-1, proprotein convertase subtilisin/kexin type 9 (PCSK9), podocalyxin, paraoxonase-3 (PON-3), prostasin, protein S100A4 (S100A4), protein S100A11 (S100A11), retinoic acid receptor responder protein 2 (RARRES2), resistin, secretory carrier-associated membrane protein 3 (SCAMP3), secretoglobin family 3A member 2 (SCGB3A2), serpin A12, tyrosine-protein phosphatase non-receptor type substrate 1 (SHPS-1), sortillin, soluble receptor for advanced glycation end products (sRAGE; all soluble forms of RAGE), T-cell leukaemia/lymphoma protein 1A (TCL1A), trefoil factor 3 (TFF3), protein-glutamine gamma-glutamyltransferase 2 (TGM2), transferrin receptor protein 1 (TR), WAP four-disulfide core domain protein 2 (WFDC2), vimentin, V-set and immunoglobulin domain-containing protein 2 (VSIG2) and Xaa-Pro aminopeptidase 2 (XPNPEP2).

Techniques: